AstraZeneca PLC (AZN) fair value analysis
Nasdaq · Updated 2026-10-19
AZN price how computed
Forward Fair Value verdict
UndervaluedAZN is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $165.41
- Sector
- Healthcare
- 12-month range
- $155.62–$209.48
- Market cap
- $257B
- From 52-week high
- -21.0%
- Shares outstanding
- 1.55B
- Rank in Healthcare by discount to fair value
- #1 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
AstraZeneca PLC is a pharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across multiple therapeutic areas including oncology, cardiovascular, respiratory, and infectious diseases. The company operates globally with a presence in numerous countries across North America, Europe, Asia, and other regions worldwide.
AZN currently ranks #1 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $257B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $61.4B
- Net margin
- 17.0%
- EPS (TTM)
- $5.90
- Gross margin
- 83.6%
- Debt / equity
- 0.64
- Revenue growth (3-yr avg)
- 11.3%
- Shares outstanding
- 1.55B
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $162.13
- 200-day average
- $180.95
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $3.22 per share (2 payments)
- Yield on last price
- 1.95%
- Consecutive years of increases
- 4
- Last ex-dividend date
- 2026-08-07
- Last payment date
- 2026-09-08
Earnings how computed
- Next earnings report
- 2026-10-30 (pre-market)
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.2%)
2026-03 ▲ beat (+1.6%)
2025-09 ▲ beat (+5.3%)
2025-06 ▼ miss (-10.2%)
2025-03 ▲ beat (+11.6%)
2024-12 ▲ beat (+1.0%)
2024-09 ▲ beat (+1.0%)
2024-06 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 1 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $207
- Target vs last price
- +25.1%
What our data shows for AZN
- Our model validated 15 trailing price-to-earnings windows for AZN, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $155.62–$209.48.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AZN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AZN news
TickrTrends' derived news-sentiment signal for AZN is currently leaning positive, computed from recent coverage.
- AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple? (insidermonkey.com, 2026-10-20)
TickrTrends take: AstraZeneca's oncology pipeline expansion represents potential future revenue growth that may not yet be fully reflected in its current earnings multiple. Given TickrTrends' undervalued assessment, investors following valuation metrics should monitor whether new oncology catalysts translate into near-term revenue recognition or remain longer-term probability-weighted bets. The healthcare sector context matters here, as oncology-focused companies typically command premium multiples during pipeline advancement phases, making execution timing relevant to whether current valuation estimates prove prescient. - AstraZeneca (AZN) Reports Positive Phase 3 CROSSING Trial Results for Eosinophilic Esophagitis Treatment (gurufocus.com, 2026-10-20)
TickrTrends take: AstraZeneca's positive Phase 3 results for an eosinophilic esophagitis treatment represent clinical validation for a potential new revenue stream in a disease area with limited therapeutic options. Given TickrTrends' undervalued assessment of AZN, this clinical success could support the stock's valuation thesis if the company successfully advances the program toward commercialization. Investors following the valuation narrative should monitor upcoming regulatory milestones and commercial guidance updates to assess whether this development justifies the current undervalued positioning. - AstraZeneca (AZN) Partners with insitro in $1.5B AI-Driven Drug Discovery Collaboration (gurufocus.com, 2026-10-15)
TickrTrends take: AstraZeneca's partnership with insitro represents a significant capital commitment to artificial intelligence-driven drug discovery, a field increasingly viewed as essential for pharmaceutical competitiveness and pipeline efficiency. Given TickrTrends' current undervalued assessment of AZN, investors focused on valuation should monitor whether this collaboration materializes into accelerated drug candidates and reduced development timelines, factors that could justify premium valuations in the future. The success of this AI partnership could serve as a key catalyst for reassessing the company's long-term earnings potential and market multiple expansion within the Healthcare sector.
More AZN news
- AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 Tells Investors (gurufocus.com, 2026-10-14)
- Top Research Reports for Mastercard, AstraZeneca & Sandisk (zacks.com, 2026-10-14)
- AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript (seekingalpha.com, 2026-10-12)
- AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting - Slideshow (NYSE:AZN) 2026-10-12 (seekingalpha.com, 2026-10-12)
- AZN DCF Analysis: Intrinsic Value $97 vs Price $157 (gurufocus.com, 2026-10-05)
What people are saying
Follow the AZN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AZN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), AZN is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is AZN's TickrTrends verdict?
AZN's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does AZN compare to other Healthcare stocks?
AZN ranks #1 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is AZN overbought or oversold?
AZN's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does AZN pay a dividend?
Yes. AZN paid $3.22 per share over the last twelve months (2 payments), a 1.95% yield on TickrTrends' last price, and has raised the annual total for 4 consecutive years. The last ex-dividend date was 2026-08-07.
When does AZN report earnings next?
AZN's next earnings report is scheduled for 2026-10-30 (pre-market), per the published earnings calendar.
Does AZN usually beat earnings estimates?
Over its last 8 reported quarters AZN beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AZN?
Of 11 analysts covering AZN, 10 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $207 (+25.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
AZN vs ADMA · AZN vs ALGN · AZN vs ANIP · AZN vs ANL · AZN vs ASTH